Kalaris Therapeutics, Inc.
Kalaris Therapeutics, Inc. scores highest on Torque (51) and lowest on Nitro (8). Its PosiPenta is 35.64 out of 100, weaker than most similar companies.
On the Penta Grid this week, Kalaris Therapeutics, Inc. is Grid #651 of 837 in the Healthcare sector in United States, and Grid #3,244 of 4,000 in United States.
Compared with similar companies in the Healthcare sector in United States.
The five pillars
Similar companies
| Company | PosiPenta | P | E | N | T | A |
|---|---|---|---|---|---|---|
| Kalaris Therapeutics, Inc. | 35.64 | 41 | 34 | 8 | 51 | 44 |
| Sensus Healthcare, Inc. | 50.09 | 37 | 61 | 38 | 66 | 49 |
| LeonaBio, Inc. | 30.10 | 33 | 4 | 43 | 39 | 32 |
| Connect Biopharma Holdings Limited | 38.74 | 28 | 45 | 22 | 45 | 54 |
| Spectral AI, Inc. | 45.19 | 0 | 35 | 47 | 97 | 46 |
| Myomo, Inc. | 37.35 | 8 | 56 | 67 | 15 | 40 |
Similar-sized companies in the same sector, this week. P Price · E Earnings · N Nitro · T Torque · A Anchor.
Details
PPrice
| P/E ratio | -0.99 |
| P/B ratio | 0.83 |
EEarnings
| Trailing EPS | ₹-191.32 |
| Forward EPS | ₹-156.52 |
NNitro
| Price | 189.43 |
| 52-week high | 1125.21 |
| 52-week low | 189.43 |
| Fall from 52-week high | 83.2% |
TTorque
| Return on equity (ROE) | -79.91% |
| Debt-to-equity | 0.02 |
AAnchor
| Beta (price swings) | — |
| Market cap | ₹450 Cr |
| Insider holding | 8.81% |
| Dividend yield | 0.00% |
Figures as used for the week of 17 Oct 2026; today's figures on the company page may differ slightly.
Questions
What is Kalaris Therapeutics, Inc.'s PosiPenta score?
Kalaris Therapeutics, Inc.'s PosiPenta is 35.64 out of 100 for the week of 17 Oct 2026, based on 5 of 5 pillars.
Where does Kalaris Therapeutics, Inc. stand on the Penta Grid?
On the Penta Grid this week, Kalaris Therapeutics, Inc. is Grid #651 of 837 in the Healthcare sector in United States, and Grid #3,244 of 4,000 in United States.
Which PosiPenta pillar is strongest for Kalaris Therapeutics, Inc.?
Torque (durability), with a score of 51 out of 100: around the middle of similar companies.
Which PosiPenta pillar is weakest for Kalaris Therapeutics, Inc.?
Nitro (momentum), with a score of 8 out of 100: much weaker than most similar companies.
Has Kalaris Therapeutics, Inc.'s PosiPenta changed since last week?
Yes, it rose 2.63 points, from 33.01 to 35.64.
PositoAI is for research and education only and is not investment advice.